Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy

Hepatology Research

Volumn 42, Issue 7, 2012, Pages 627-636

  Oketani, Makoto ^a   Ido, Akio ^a   Uto, Hirofumi ^a   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

De novo hepatitis; Fulminant hepatitis; Hepatitis B virus reactivation; Immunosuppressive therapy; Rituximab

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; METHOTREXATE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; JAPAN; LIVER FAILURE; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84862269632     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00998.x     Document Type: Article

References (75)

1. Tanaka J, Kumagai J, Katayama K etal. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3485648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
2. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 (Suppl 1): 3-8.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
4. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
5. Rotman Y, Brown TA, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology 2009; 49 (Suppl 5): S22-7.
6. Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007; 1: 311-5.
7. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-5.
8. Kumagai K, Takagi T, Nakamura S etal. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl 1): 107-9.
9. Yeo W, Lam KC, Zee B etal. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-6.
10. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-8.
11. Yeo W, Zee B, Zhong S etal. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
12. Yeo W, Chan PK, Zhong S etal. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
13. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
14. Yeo W, Chan PK, Hui P etal. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-61.
15. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540-6.
16. Takai S, Tsurumi H, Ando K etal. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158-65.
17. Marcucci F, Mele A, Spada E etal. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-7.
18. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83: 1627-31.
19. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13: 14-20.
20. Hsu CH, Hsu HC, Chen HL etal. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004; 24: 3035-40.
21. Hui CK, Bowden S, Jackson K etal. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005; 105: 2616-7.
22. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257-9.
23. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-6.
24. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
25. Tsutsumi Y, Shigematsu A, Hashino S etal. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009; 88: 375-7.
26. Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008; 87: 325-7.
27. Yeo W, Chan TC, Leung NW etal. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
28. Tanaka Y, Esumi M, Shikata T. Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver 1990; 10: 6-10.
29. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-42.
30. Penna A, Artini M, Cavalli A etal. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
31. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
32. Yeo W, Johanson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
33. Xunrong L, Yan AW, Liang R etal. Hepatitis B virus(HBG) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol 2001; 11: 287-99.
34. Kitano K, Kobayashi H, Hanamura M etal. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promoter region. Eur J Hematol 2006; 77: 255-58.
35. Hui CK, Cheung WW, Zhang HY etal. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
36. Westhoff TH, Jochimsen F, Schmittel A etal. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
37. Umemura T, Tanaka E, Kiyosawa K etal. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-6.
38. Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 65-71.
39. Coppola N, Tonziello G, Pisaturo M etal. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011; 83: 1909-16.
40. Yeo W, Chan PK, Ho WM etal. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
41. Hsu C, Hsiung CA, Su IJ etal. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
42. Lau GK, He ML, Fong DY etal. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-9.
43. Loomba R, Rowley A, Wesley R etal. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
44. Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 2006; 81: 969-72.
45. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
46. Colonno RJ, Rose R, Baldick CJ etal. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-65.
47. Tenney DJ, Rose RE, Baldick CJ etal. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11.
48. Watanabe M, Shibuya A, Takada J etal. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21: 333-7.
49. Tamori A, Koike T, Goto H etal. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-64.
50. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
51. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
52. Yokosuka O, Kurosaki M, Imazeki F etal. Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011; 41: 1-21.
53. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-71.
54. Hui CK, Cheung WW, Au WY etal. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-603.
55. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the "a" determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol 2004; 17: 440-4.
56. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
57. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-40.
58. Awerkiew S, Däumer M, Reiser M etal. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-6.
59. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-57.
60. Fukushima N, Mizuta T, Tanaka M etal. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20: 2013-7.
61. Onozawa M, Hashino S, Izumiyama K etal. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-9.
62. Goyama S, Kanda Y, Nannya Y etal. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 2159-63.
63. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapy. J Clin Oncol 2011; 29: e100.
64. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010; 28: 5097-100.
65. Yaǧci M, Ozkurt ZN, Yeǧin ZA, Aki Z, Sucak GT, Haznedar R. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010; 15: 240-4.
66. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-91.
67. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-74.
68. Tsubouch H, Kumada H, Kiyosawa K etal. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection.-joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Acta Hepatol Jpn 2009; 50: 38-42. (in Japanese.)
69. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25: 888-9.
70. Ito S, Nakazono K, Murasawa A etal. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-42.
71. Ojiro K, Naganuma M, Ebinuma H etal. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401.
72. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
73. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705-12.
74. Urata Y, Uesato R, Tanaka D etal. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
75. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-7.